Categories: Health

Covid-19: Hope for the immunocompromised as sipavibart approaches market

The European Medicines Agency (EMA) has granted an accelerated regulatory approval for AstraZeneca’s sipavibart for marketing for the prevention of Covid-19 in immunocompromised patients.

The drug is a long-acting antibody (LAAB) in the study stage, the pharmaceutical company said Monday, designed to provide protection against Covid-19 in immunocompromised patients who do not respond adequately to vaccination and who are at high risk of serious complications from the disease.

The EMA Committee for Medicinal Products for Human Use (CMH) granted this LAAB an accelerated assessment as it was considered to be of high interest for public health and therapeutic innovation. The aim of this accelerated assessment is to reduce the time it takes the CMH to review a Marketing Authorisation Application (MAA) compared to the standard procedure.

The marketing authorisation is based on positive results from the phase III Supernova study, which demonstrated the safety and efficacy of this LAAB in preventing symptomatic Covid-19 in immunocompromised patients compared to controls in a variant panorama in which the Covid-19 cases identified in the study were caused by several different SARS-CoV-2 variants.

Supernova is a Phase III study providing data on the efficacy of pre-exposure prophylaxis against Covid-19 exclusively in immunocompromised patients.

IMMUNOSUPPRESSION

In this regard, Dr. Paul Loubet, professor of infectious diseases at the University of Montpellier, head of the infectious and tropical diseases department at the University Hospital of Nîmes (France) and researcher in the Supernova study, stressed that “the burden of Covid-19 remains high among immunocompromised patients, who suffer disproportionately compared to the general population, despite vaccination.”

“With case numbers expected to increase during the winter months, putting additional pressure on overstretched healthcare systems, this LAAB may be an option for immunocompromised patients who remain at risk and has demonstrated protection against Covid-19 in a mixed environment,” he added.

For her part, AstraZeneca’s executive vice president for vaccines and immunotherapy, Iskra Reich, noted that “immunocompromised patients in Europe currently have no new option to protect themselves from Covid-19 other than vaccination, which is often unavailable. This is enough to protect them from the serious consequences of this disease.”

He therefore added: “We are pleased that the EMA has accepted this regulatory submission with an accelerated assessment procedure and we will work to bring this LAAB to these extremely vulnerable patients.”

PERMISSION OR APPROVAL

Data from the Supernova trial will soon be presented at a scientific forum. In addition to the EMA, AstraZeneca is in dialogue with other regulators about possible paths to authorisation or approval.

Positive SUPERNOVA results showed a statistically significant reduction in the incidence of symptomatic Covid-19 in the antibody-treated group compared to controls, demonstrating a reduction in the relative risk of symptomatic disease caused by any SARS-CoV 2 variant and a relative reduction in the risk of infections caused by SARS-CoV-2 variants that do not contain the F456L mutation.

Overall, the drug was well tolerated during the study, and preliminary analyses showed that side effects were balanced between control groups.

Source link

Admin

Share
Published by
Admin

Recent Posts

Notre Selection du Samedi November 2

Ce soir, on le choix entre passer la soirée avec Saoirse Ronan in "Lady Bird",…

10 mins ago

US Elections 2024 | Vote amid concern and disbelief

The bodies of more than 3,000 southern soldiers, including 2,184 unidentified, remain. Fredericksburg Confederate Cemetery,…

13 mins ago

Why do women suffer more from this, according to a neurophysiologist?

According to data European Health Study in Spaincarried out in 2020 by the National Institute…

15 mins ago

Banking tax fiasco: for every euro collected, private sector funding falls by 17 euros

While The government is working to make the "extraordinary profits" tax permanent.“From banking, financial institutions…

22 mins ago

This star rotates at a speed of 716 times per second – the fastest rotation in the Universe.

Located 26,000 light-years from Earth, the neutron star 4U 1820-30, along with the white dwarf…

24 mins ago

Malaysian MotoGP sprint race: results, results and reaction in Sepang

The sprint race in Sepang is over. We'll be back tomorrow with appointments for Moto3…

26 mins ago